1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 74, 2023
  5. Article

Annual Review of Medicine

Volume 74, 2023

All the Tau We Cannot See

Abstract

Alzheimer's disease (AD) was described in 1906 as a dementing disease marked by the presence of two types of fibrillar aggregates in the brain: neurofibrillary tangles and senile plaques. The process of aggregation and formation of the aggregates has been a major focus of investigation ever since the discoveries that the tau protein is the predominant protein in tangles and amyloid β is the predominant protein in plaques. The idea that smaller, oligomeric species of amyloid may also be bioactive has now been clearly established. This review examines the possibility that soluble, nonfibrillar, bioactive forms of tau—the “tau we cannot see”—comprise a dominant driver of neurodegeneration in AD.

Keyword(s): Alzheimer, biomarker, neurofibrillary tangle, tau, therapeutics
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042921-023749
2023-01-27
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-042921-023749.html?itemId=/content/journals/10.1146/annurev-med-042921-023749&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Hyman BT, Phelps CH, Beach TG et al. 2012. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8:1–13
     [Google Scholar]
  2. 2.
    Montine TJ, Phelps CH, Beach TG et al. 2012. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123:1–11
     [Google Scholar]
  3. 3.
    Ronald and Nancy Reagan Res. Inst. Alzheimer's Assoc. and Natl. Inst. Aging Work. Group 1998. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer's Disease. .” Neurobiol. Aging 19:109–16
     [Google Scholar]
  4. 4.
    Brotzakis ZF, Lindstedt PR, Taylor RJ et al. 2021. A structural ensemble of a tau-microtubule complex reveals regulatory tau phosphorylation and acetylation mechanisms. ACS Cent. Sci. 7:1986–95
     [Google Scholar]
  5. 5.
    Carlomagno Y, Manne S, DeTure M et al. 2021. The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Rep. 34:108843
     [Google Scholar]
  6. 6.
    Falcon B, Zhang W, Murzin AG et al. 2018. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 561:137–40
     [Google Scholar]
  7. 7.
    Falcon B, Zhang W, Schweighauser M et al. 2018. Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathol. 136:699–708
     [Google Scholar]
  8. 8.
    Scheres SH, Zhang W, Falcon B, Goedert M. 2020. Cryo-EM structures of tau filaments. Curr. Opin. Struct. Biol. 64:17–25
     [Google Scholar]
  9. 9.
    Zhang W, Tarutani A, Newell KL et al. 2020. Novel tau filament fold in corticobasal degeneration. Nature 580:283–87
     [Google Scholar]
  10. 10.
    Dujardin S, Commins C, Lathuiliere A et al. 2020. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat. Med. 26:1256–63
     [Google Scholar]
  11. 11.
    Wesseling H, Mair W, Kumar M et al. 2020. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer's disease. Cell 183:1699–713.e13
     [Google Scholar]
  12. 12.
    Johnson KA, Schultz A, Betensky RA et al. 2016. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79:110–19
     [Google Scholar]
  13. 13.
    Xia C, Makaretz SJ, Caso C et al. 2017. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 74:427–36
     [Google Scholar]
  14. 14.
    Kopeikina KJ, Hyman BT, Spires-Jones TL. 2012. Soluble forms of tau are toxic in Alzheimer's disease. Transl. Neurosci. 3:223–33
     [Google Scholar]
  15. 15.
    Leon-Espinosa G, Garcia E, Garcia-Escudero V et al. 2013. Changes in tau phosphorylation in hibernating rodents. J. Neurosci. Res. 91:954–62
     [Google Scholar]
  16. 16.
    Gomez-Isla T, Hollister R, West H et al. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:17–24
     [Google Scholar]
  17. 17.
    Perez-Nievas BG, Stein TD, Tai HC et al. 2013. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 136:2510–26
     [Google Scholar]
  18. 18.
    Santacruz K, Lewis J, Spires T et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–81
     [Google Scholar]
  19. 19.
    Fox LM, William CM, Adamowicz DH et al. 2011. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J. Neuropathol. Exp. Neurol. 70:588–95
     [Google Scholar]
  20. 20.
    Polydoro M, Dzhala VI, Pooler AM et al. 2014. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol. 127:257–70
     [Google Scholar]
  21. 21.
    Rudinskiy N, Hawkes JM, Betensky RA et al. 2012. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat. Neurosci. 15:1422–29
     [Google Scholar]
  22. 22.
    Rudinskiy N, Hawkes JM, Wegmann S et al. 2014. Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathol. Commun. 2:63
     [Google Scholar]
  23. 23.
    Busche MA, Hyman BT. 2020. Synergy between amyloid-beta and tau in Alzheimer's disease. Nat. Neurosci. 23:1183–93
     [Google Scholar]
  24. 24.
    Busche MA, Wegmann S, Dujardin S et al. 2019. Tau impairs neural circuits, dominating amyloid-beta effects, in Alzheimer models in vivo. Nat. Neurosci. 22:57–64
     [Google Scholar]
  25. 25.
    Wegmann S, DeVos SL, Zeitler B et al. 2021. Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Sci. Adv. 7:eabe1611
     [Google Scholar]
  26. 26.
    Alonso AD, Cohen LS, Corbo C et al. 2018. Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability. Front. Cell Neurosci. 12:338
     [Google Scholar]
  27. 27.
    Hernandez-Vega A, Braun M, Scharrel L et al. 2017. Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase. Cell Rep. 20:2304–12
     [Google Scholar]
  28. 28.
    Kellogg EH, Hejab NMA, Poepsel S et al. 2018. Near-atomic model of microtubule-tau interactions. Science 360:1242–46
     [Google Scholar]
  29. 29.
    Prezel E, Elie A, Delaroche J et al. 2018. Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles. Mol. Biol. Cell 29:154–65
     [Google Scholar]
  30. 30.
    Ando K, Maruko-Otake A, Ohtake Y et al. 2016. Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and Aβ42-induced tau toxicity. PLOS Genet. 12:e1005917
     [Google Scholar]
  31. 31.
    Dickson JR, Yoon H, Frosch MP, Hyman BT. 2021. Cytoplasmic mislocalization of RNA polymerase II subunit RPB1 in Alzheimer disease is linked to pathologic tau. J. Neuropathol. Exp. Neurol. 80:530–40
     [Google Scholar]
  32. 32.
    DuBoff B, Gotz J, Feany MB. 2012. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75:618–32
     [Google Scholar]
  33. 33.
    Eftekharzadeh B, Daigle JG, Kapinos LE et al. 2018. Tau protein disrupts nucleocytoplasmic transport in Alzheimer's disease. Neuron 99:925–40.e7
     [Google Scholar]
  34. 34.
    Gilley J, Ando K, Seereeram A et al. 2016. Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice. Neurobiol. Aging 39:1–18
     [Google Scholar]
  35. 35.
    Hoover BR, Reed MN, Su J et al. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067–81
     [Google Scholar]
  36. 36.
    Iwata M, Watanabe S, Yamane A et al. 2019. Regulatory mechanisms for the axonal localization of tau protein in neurons. Mol. Biol. Cell 30:2441–57
     [Google Scholar]
  37. 37.
    McMillan PJ, Strovas TJ, Baum M et al. 2021. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease. Acta Neuropathol. Commun. 9:117
     [Google Scholar]
  38. 38.
    Pir GJ, Choudhary B, Mandelkow E, Mandelkow EM. 2016. Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans tauopathy model. Mol. Neurodegener. 11:33
     [Google Scholar]
  39. 39.
    Sohn PD, Tracy TE, Son HI et al. 2016. Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol. Neurodegener. 11:47
     [Google Scholar]
  40. 40.
    Stoothoff W, Jones PB, Spires-Jones TL et al. 2009. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem. 111:417–27
     [Google Scholar]
  41. 41.
    Zempel H, Dennissen FJA, Kumar Y et al. 2017. Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. J. Biol. Chem. 292:12192–207
     [Google Scholar]
  42. 42.
    Zempel H, Mandelkow EM. 2015. Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer disease and hereditary spastic paraplegia. Mol. Neurodegener. 10:68
     [Google Scholar]
  43. 43.
    de Calignon A, Fox LM, Pitstick R et al. 2010. Caspase activation precedes and leads to tangles. Nature 464:1201–4
     [Google Scholar]
  44. 44.
    de Calignon A, Spires-Jones TL, Pitstick R et al. 2009. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68:757–61
     [Google Scholar]
  45. 45.
    Jiang S, Maphis NM, Binder J et al. 2021. Proteopathic tau primes and activates interleukin-1β via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep. 36:109720
     [Google Scholar]
  46. 46.
    Kaushal V, Dye R, Pakavathkumar P et al. 2015. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 22:1676–86
     [Google Scholar]
  47. 47.
    Lempriere S. 2020. NLRP3 inflammasome activation implicated in tau pathology. Nat. Rev. Neurol. 16:4
     [Google Scholar]
  48. 48.
    Oakley DH, Klickstein N, Commins C et al. 2021. Continuous monitoring of tau-induced neurotoxicity in patient-derived iPSC-neurons. J. Neurosci. 41:4335–48
     [Google Scholar]
  49. 49.
    Perez MJ, Vergara-Pulgar K, Jara C et al. 2018. Caspase-cleaved tau impairs mitochondrial dynamics in Alzheimer's disease. Mol. Neurobiol. 55:1004–18
     [Google Scholar]
  50. 50.
    Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV. 2009. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem. 284:18754–66
     [Google Scholar]
  51. 51.
    Spires-Jones TL, de Calignon A, Matsui T et al. 2008. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J. Neurosci. 28:862–67
     [Google Scholar]
  52. 52.
    Tracy TE, Madero-Perez J, Swaney DL et al. 2022. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell 185:712–28.e14
     [Google Scholar]
  53. 53.
    Lombardo JA, Stern EA, McLellan ME et al. 2003. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23:10879–83
     [Google Scholar]
  54. 54.
    Wee M, Chegini F, Power JHT, Majd S. 2018. Tau positive neurons show marked mitochondrial loss and nuclear degradation in Alzheimer's disease. Curr. Alzheimer Res. 15:928–37
     [Google Scholar]
  55. 55.
    Hachiya N, Sochocka M, Brzecka A et al. 2021. Nuclear envelope and nuclear pore complexes in neurodegenerative diseases—new perspectives for therapeutic interventions. Mol. Neurobiol. 58:983–95
     [Google Scholar]
  56. 56.
    de Calignon A, Polydoro M, Suarez-Calvet M et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685–97
     [Google Scholar]
  57. 57.
    Meisl G, Hidari E, Allinson K et al. 2021. In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. Sci. Adv. 7:eabh1448
     [Google Scholar]
  58. 58.
    Cooper JM, Lathuiliere A, Migliorini M et al. 2021. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J. Biol. Chem. 296:100715
     [Google Scholar]
  59. 59.
    Rauch JN, Luna G, Guzman E et al. 2020. LRP1 is a master regulator of tau uptake and spread. Nature 580:381–85
     [Google Scholar]
  60. 60.
    Kounnas MZ, Moir RD, Rebeck GW et al. 1995. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82:331–40
     [Google Scholar]
  61. 61.
    Lleo A, Waldron E, von Arnim CA et al. 2005. Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. J. Biol. Chem. 280:27303–9
     [Google Scholar]
  62. 62.
    Rebeck GW, Moir RD, Mui S et al. 2001. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res. Mol. Brain Res. 87:238–45
     [Google Scholar]
  63. 63.
    Ruiz J, Kouiavskaia D, Migliorini M et al. 2005. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46:1721–31
     [Google Scholar]
  64. 64.
    Ulery PG, Beers J, Mikhailenko I et al. 2000. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J. Biol. Chem. 275:7410–15
     [Google Scholar]
  65. 65.
    von Arnim CA, Kinoshita A, Peltan ID et al. 2005. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem. 280:17777–85
     [Google Scholar]
  66. 66.
    Koh YH, von Arnim CA, Hyman BT et al. 2005. BACE is degraded via the lysosomal pathway. J. Biol. Chem. 280:32499–504
     [Google Scholar]
  67. 67.
    Takeda S, Commins C, DeVos SL et al. 2016. Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. Ann. Neurol. 80:355–67
     [Google Scholar]
  68. 68.
    Kim C, Haldiman T, Kang SG et al. 2022. Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer's disease. Sci. Transl. Med. 14:eabg0253
     [Google Scholar]
  69. 69.
    Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E et al. 2021. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathol. 141:217–33
     [Google Scholar]
  70. 70.
    Wegmann S, Eftekharzadeh B, Tepper K et al. 2018. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 37:e98049
     [Google Scholar]
  71. 71.
    Wu HY, Kuo PC, Wang YT et al. 2018. β-Amyloid induces pathology-related patterns of tau hyperphosphorylation at synaptic terminals. J. Neuropathol. Exp. Neurol. 77:814–26
     [Google Scholar]
  72. 72.
    Tai HC, Wang BY, Serrano-Pozo A et al. 2014. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. Acta Neuropathol. Commun. 2:146
     [Google Scholar]
  73. 73.
    DeVos SL, Corjuc BT, Oakley DH et al. 2018. Synaptic tau seeding precedes tau pathology in human Alzheimer's disease brain. Front. Neurosci. 12:267
     [Google Scholar]
  74. 74.
    Geddes JW, Monaghan DT, Cotman CW et al. 1985. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 230:1179–81
     [Google Scholar]
  75. 75.
    Hyman BT, Kromer LJ, Van Hoesen GW. 1987. Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease. Ann. Neurol. 21:259–67
     [Google Scholar]
  76. 76.
    Barthelemy NR, Horie K, Sato C, Bateman RJ. 2020. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J. Exp. Med. 217:e20200861
     [Google Scholar]
  77. 77.
    Chhatwal JP, Schultz AP, Dang Y et al. 2020. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat. Commun. 11:6024
     [Google Scholar]
  78. 78.
    Clark C, Lewczuk P, Kornhuber J et al. 2021. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. Alzheimers Res. Ther. 13:65
     [Google Scholar]
  79. 79.
    Garcia-Moreno H, Prudencio M, Thomas-Black G et al. 2022. Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3. Eur. J. Neurol. 29:2439–52
     [Google Scholar]
  80. 80.
    Hall S, Janelidze S, Londos E et al. 2021. Plasma phospho-tau identifies Alzheimer's co-pathology in patients with Lewy body disease. Mov. Disord. 36:767–71
     [Google Scholar]
  81. 81.
    Kojima Y, Kasai T, Noto YI et al. 2021. Amyotrophic lateral sclerosis: correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLOS ONE 16:e0260323
     [Google Scholar]
  82. 82.
    Mattsson-Carlgren N, Janelidze S, Bateman RJ et al. 2021. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. 13:e14022
     [Google Scholar]
  83. 83.
    Mengel D, Mok TH, Nihat A et al. 2021. NT1-tau is increased in CSF and plasma of CJD patients, and correlates with disease progression. Cells 10:3514
     [Google Scholar]
  84. 84.
    Rauchmann BS, Schneider-Axmann T, Perneczky R et al. 2021. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition. J. Neurol. Neurosurg. Psychiatry 92:1289–95
     [Google Scholar]
  85. 85.
    Thijssen EH, La Joie R, Strom A et al. 2021. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20:739–52
     [Google Scholar]
  86. 86.
    Mielke MM, Dage JL, Frank RD et al. 2022. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28:1398–405
     [Google Scholar]
  87. 87.
    Kac PR, Gonzalez-Ortiz F, Simren J et al. 2022. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. Alzheimers Res. Ther. 14:65
     [Google Scholar]
  88. 88.
    Cullen NC, Janelidze S, Mattsson-Carlgren N et al. 2022. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimers Dement. 2022:1–10
     [Google Scholar]
  89. 89.
    Qin W, Li F, Jia L et al. 2022. Phosphorylated tau 181 serum levels predict Alzheimer's disease in the preclinical stage. Front. Aging Neurosci. 14:900773
     [Google Scholar]
  90. 90.
    Ossenkoppele R, van der Kant R, Hansson O. 2022. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurol. 21:726–34
     [Google Scholar]
  91. 91.
    Asken BM, Tanner JA, VandeVrede L et al. 2022. Plasma P-tau181 and P-tau217 in patients with traumatic encephalopathy syndrome with and without evidence of Alzheimer disease pathology. Neurology 99:e594–604
     [Google Scholar]
  92. 92.
    Illan-Gala I, Lleo A, Karydas A et al. 2021. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology 96:e671–83
     [Google Scholar]
  93. 93.
    Budd Haeberlein S, Aisen PS, Barkhof F et al. 2022. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J. Prev. Alzheimers Dis. 9:197–210
     [Google Scholar]
/content/journals/10.1146/annurev-med-042921-023749
Loading
All the Tau We Cannot See
Annual Review of Medicine 74, 503 (2023); https://doi.org/10.1146/annurev-med-042921-023749
/content/journals/10.1146/annurev-med-042921-023749
/content/journals/10.1146/annurev-med-042921-023749
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error